Matthew Holderfield

3.7k total citations · 1 hit paper
25 papers, 2.2k citations indexed

About

Matthew Holderfield is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Matthew Holderfield has authored 25 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Matthew Holderfield's work include Melanoma and MAPK Pathways (9 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Angiogenesis and VEGF in Cancer (5 papers). Matthew Holderfield is often cited by papers focused on Melanoma and MAPK Pathways (9 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Angiogenesis and VEGF in Cancer (5 papers). Matthew Holderfield collaborates with scholars based in United States, Switzerland and Finland. Matthew Holderfield's co-authors include Frank McCormick, Christopher C.W. Hughes, Martin McMahon, Marian M. Deuker, Erin M. Conn, Martin N. Nakatsu, Richard C.A. Sainson, Darrin D. Stuart, Tobi Nagel and Douglas A. Johnston and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nature reviews. Cancer.

In The Last Decade

Matthew Holderfield

25 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

2014 618 citations Matthew Holderfield, Marian M. Deuker et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Holderfield United States	17	1.7k	564	281	266	219	25	2.2k
Bruno Alicke United States	21	1.8k 1.0×	566 1.0×	120 0.4×	215 0.8×	158 0.7×	32	2.3k
Antonella Bacchiocchi United States	18	1.1k 0.7×	1.3k 2.2×	250 0.9×	312 1.2×	627 2.9×	32	2.4k
Natalia Jura United States	25	2.1k 1.2×	1.3k 2.2×	423 1.5×	248 0.9×	237 1.1×	50	3.2k
Mercedes Lioni United States	11	833 0.5×	697 1.2×	209 0.7×	180 0.7×	132 0.6×	11	1.4k
Jasper Mullenders Netherlands	17	2.0k 1.2×	651 1.2×	157 0.6×	440 1.7×	192 0.9×	25	2.7k
David R. Croucher Australia	24	1.3k 0.7×	507 0.9×	338 1.2×	486 1.8×	232 1.1×	47	2.1k
Gregory J. Riggins United States	21	1.0k 0.6×	432 0.8×	93 0.3×	326 1.2×	116 0.5×	35	1.9k
Xiaohong Leng United States	19	1.2k 0.7×	650 1.2×	271 1.0×	207 0.8×	287 1.3×	32	2.0k
Péter Sandy United States	17	3.0k 1.8×	994 1.8×	203 0.7×	429 1.6×	258 1.2×	27	3.5k
Morgan O’Hayre United States	14	927 0.5×	421 0.7×	151 0.5×	141 0.5×	285 1.3×	18	1.5k

Countries citing papers authored by Matthew Holderfield

Since Specialization

Citations

This map shows the geographic impact of Matthew Holderfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Holderfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Holderfield more than expected).

Fields of papers citing papers by Matthew Holderfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Holderfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Holderfield. The network helps show where Matthew Holderfield may publish in the future.

Co-authorship network of co-authors of Matthew Holderfield

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Holderfield. A scholar is included among the top collaborators of Matthew Holderfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Holderfield. Matthew Holderfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seamon, Kenneth B., Sohini Chakraborty, Jim Cregg, et al.. (2024). 92 (PB080): Selective Inhibition of Active KRASG13C with RMC-8839 Reveals an Increased Dependence of Codon-13 KRAS-Mutant Cancers on Wild- Type RAS Isoforms. European Journal of Cancer. 211. 114618–114618. 1 indexed citations

Lai, Lo, Kanika Sharma, N. Muzet, et al.. (2021). Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition. SLAS DISCOVERY. 26(7). 922–932. 1 indexed citations

Kopra, Kari, et al.. (2020). Homogeneous Dual-Parametric-Coupled Assay for Simultaneous Nucleotide Exchange and KRAS/RAF-RBD Interaction Monitoring. Analytical Chemistry. 92(7). 4971–4979. 37 indexed citations

Yi, Ming, et al.. (2020). Abstract B18: Clostridium perfringens lethal toxin specifically targets RAS and disrupts RAS signaling pathway. Molecular Cancer Research. 18(5_Supplement). B18–B18. 1 indexed citations

Tran, Timothy H., Srisathiyanarayanan Dharmaiah, Robert M. Stephens, et al.. (2019). KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis. Proceedings of the National Academy of Sciences. 116(44). 22122–22131. 94 indexed citations

Kopra, Kari, et al.. (2018). Label-Free Time-Gated Luminescent Detection Method for the Nucleotides with Varying Phosphate Content. Sensors. 18(11). 3989–3989. 2 indexed citations

Esposito, Dominic, Andrew G. Stephen, Thomas J. Turbyville, & Matthew Holderfield. (2018). New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics. Seminars in Cancer Biology. 54. 174–182. 11 indexed citations

Holderfield, Matthew. (2017). Efforts to Develop KRAS Inhibitors. Cold Spring Harbor Perspectives in Medicine. 8(7). a031864–a031864. 32 indexed citations

Ritt, Daniel A., Maria Teresa Abreu‐Blanco, Lakshman Bindu, et al.. (2016). Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. Molecular Cell. 64(5). 875–887. 76 indexed citations

10.

Gillette, William, Dominic Esposito, Patrick Alexander, et al.. (2015). Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions. Scientific Reports. 5(1). 15916–15916. 56 indexed citations

11.

Holderfield, Matthew, Jacqueline Galeas, Reyno Delrosario, et al.. (2015). K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell. 163(5). 1237–1251. 155 indexed citations

12.

Holderfield, Matthew, Edward Lorenzana, Ben Weisburd, et al.. (2014). Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Research. 74(8). 2238–2245. 20 indexed citations

13.

Holderfield, Matthew, et al.. (2014). Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation. Genome biology. 15(10). 476–476. 145 indexed citations

14.

Holderfield, Matthew, Tobi Nagel, & Darrin D. Stuart. (2014). Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. British Journal of Cancer. 111(4). 640–645. 90 indexed citations

15.

Holderfield, Matthew, Marian M. Deuker, Frank McCormick, & Martin McMahon. (2014). Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nature reviews. Cancer. 14(7). 455–467. 618 indexed citations breakdown →

16.

Ziegler, Mary E., Xiaofang Chen, Matthew Holderfield, et al.. (2014). Interferon-Induced Transmembrane Protein 1 Regulates Endothelial Lumen Formation During Angiogenesis. Arteriosclerosis Thrombosis and Vascular Biology. 34(5). 1011–1019. 30 indexed citations

17.

Holderfield, Matthew, Hanne Merritt, John S.D. Chan, et al.. (2013). RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation. Cancer Cell. 23(5). 594–602. 96 indexed citations

18.

Sainson, Richard C.A., Douglas A. Johnston, Matthew Holderfield, et al.. (2008). TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood. 111(10). 4997–5007. 274 indexed citations

19.

Holderfield, Matthew, et al.. (2006). HESR1/CHF2 suppresses VEGFR2 transcription independent of binding to E-boxes. Biochemical and Biophysical Research Communications. 346(3). 637–648. 33 indexed citations

20.

Sainson, Richard C.A., Jason Aoto, Martin N. Nakatsu, et al.. (2005). Cell‐autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. The FASEB Journal. 19(8). 1027–1029. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact